Abstract

BackgroundAntibodies to key Plasmodium falciparum surface antigens have been shown to be important effectors that mediate clinical immunity to malaria. The cross-strain fraction of anti-malarial antibodies may however be required to achievestrain-transcending immunity. Such antibody responses against Plasmodium falciparum apical membrane antigen 1 (PfAMA1), a vaccine target molecule that is expressed in both liver and blood stages of the parasite, can be elicited through immunization with a mixture of allelic variants of the parasite molecule. Cross-strain antibodies are most likely elicited against epitopes that are shared by the allelic antigens in the vaccine cocktail.MethodsA standard competition ELISA was used to address whether the antibody response can be further focused on shared epitopes by exclusively boosting these common determinants through immunization of rabbits with different PfAMA1 alleles in sequence. The in vitro parasite growth inhibition assay was used to further evaluate the functional effects of the broadened antibody response that is characteristic of multi-allele vaccine strategies.ResultsA mixed antigen immunization protocol elicited humoral responses that were functionally similar to those elicited by a sequential immunization protocol (p > 0.05). Sequential exposure to the different PfAMA1 allelic variants induced immunological recall of responses to previous alleles and yielded functional cross-strain antibodies that would be capable of optimal growth inhibition of variant parasites at high enough concentrations.ConclusionsThese findings may have implications for the current understanding of the natural acquisition of clinical immunity to malaria as well as for rational vaccine design.

Highlights

  • Antibodies to key Plasmodium falciparum surface antigens have been shown to be important effectors that mediate clinical immunity to malaria

  • 1 - 3 were immunized with three Plasmodium falciparum apical membrane antigen 1 (PfAMA1) allelic antigens in three different sequences

  • The fourth group of rabbits was immunized with a cocktail of the three PfAMA1 alleles, while the fifth group was immunized with a mixture of the three Diversity covering proteins (DiCo mix) at all immunization time points

Read more

Summary

Introduction

Antibodies to key Plasmodium falciparum surface antigens have been shown to be important effectors that mediate clinical immunity to malaria. The cross-strain fraction of anti-malarial antibodies may be required to achieve strain-transcending immunity Such antibody responses against Plasmodium falciparum apical membrane antigen 1 (PfAMA1), a vaccine target molecule that is expressed in both liver and blood stages of the parasite, can be elicited through immunization with a mixture of allelic variants of the parasite molecule. Polymorphism in such well-known vaccine targets as the Merozoite Surface Proteins (MSPs) and Apical Membrane Antigen 1 (AMA1) have been associated with host immune pressure on parasites [6,7,8,9,10] This presents malaria vaccine researchers with a formidable challenge since immunization with one variant of these polymorphic antigens induces antibodies that show limited cross-inhibition/recognition of parasites expressing other allelic variants of the same antigen. This has been demonstrated extensively in animal models [11,12] and to some extent in human field studies [13,14,15,16]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call